| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | APOC4 |
| Uniprot No | P55056 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 27-127aa |
| 氨基酸序列 | CQPEAQEGTLSPPPKLKMSRWSLVRGRMKELLETVVNRTRDGWQWFWSPSTFRGFMQTYYDDHLRDLGPLTKAWFLESKDSLLKKTHSLCPRLVCGDKDQG |
| 预测分子量 | 13.8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于APOC4重组蛋白的3篇假设参考文献及其摘要概括(注：文献为虚构示例，实际文献需通过数据库检索)：
---
1. **文献名称**：*Recombinant APOC4 Expression in Escherichia coli: Purification and Functional Analysis*
**作者**：Smith, J., et al.
**摘要**：研究利用大肠杆菌系统表达重组人源APOC4蛋白，优化纯化步骤并验证其与脂蛋白的结合活性，为体外脂代谢研究提供工具。
2. **文献名称**：*Role of APOC4 in Lipid Metabolism: Insights from Recombinant Protein Studies*
**作者**：Lee, S., & Kim, H.
**摘要**：通过哺乳动物细胞表达重组APOC4.发现其调控低密度脂蛋白(LDL)受体活性的新机制，提示其在动脉粥样硬化中的潜在作用。
3. **文献名称**：*Structural Characterization of Recombinant APOC4 Using NMR Spectroscopy*
**作者**：Garcia, R., et al.
**摘要**：首次报道重组APOC4的溶液结构，通过核磁共振技术解析其三维构象，揭示特定结构域与脂质相互作用的分子基础。
---
如需真实文献，建议通过PubMed、Google Scholar等平台检索关键词“APOC4 recombinant protein”或“APOC4 expression”。
**Background of APOC4 Recombinant Protein**
Apolipoprotein C-IV (APOC4), a member of the apolipoprotein family, is a small protein primarily associated with lipid metabolism and lipoprotein regulation. It is encoded by the *APOC4* gene, located within the APOE/APOC1/APOC4/APOC2 gene cluster on human chromosome 19. APOC4 is expressed predominantly in the liver and plays a role in modulating the metabolism of triglyceride-rich lipoproteins, such as very-low-density lipoproteins (VLDL) and chylomicrons, by interacting with enzymes like lipoprotein lipase (LPL) and hepatic lipase.
The recombinant APOC4 protein is engineered using biotechnological methods, such as expression in *E. coli* or mammalian cell systems, to produce a purified, functional form of the protein for research applications. Recombinant technology ensures high purity, consistency, and scalability, addressing challenges associated with isolating APOC4 from natural sources.
Studies on APOC4 have gained attention due to its potential links to metabolic disorders, including dyslipidemia, cardiovascular diseases, and neurodegenerative conditions like Alzheimer’s disease. Its involvement in lipid homeostasis and inflammation pathways highlights its therapeutic and diagnostic potential. Recombinant APOC4 is widely used in *in vitro* and *in vivo* studies to elucidate its structure-function relationships, ligand interactions, and regulatory mechanisms. Additionally, it serves as a critical reagent in drug discovery, biomarker development, and studies exploring lipid-protein interactions.
Despite progress, the precise physiological roles of APOC4 remain partially understood, necessitating further research to unravel its contributions to health and disease. The availability of recombinant APOC4 accelerates mechanistic studies, offering insights into its dual roles in lipid metabolism and disease pathogenesis.
×
